Edgestream Partners’s Nektar Therapeutics NKTR Stock Holding History

Edgestream Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-31,802	Closed	-$335K	–	854
2023 Q1	$335K	Sell	31,802 -8,788	-22%	-$266K	0.04%	459
2022 Q4	$1.38M	Sell	40,590 -29,252	-42%	-$1.42M	0.15%	210
2022 Q3	$3.35M	Sell	69,842 -1,277	-2%	-$76K	0.26%	139
2022 Q2	$4.05M	Buy	71,119 +29,539	+71%	+$1.86M	0.32%	93
2022 Q1	$3.36M	Buy	41,580 +38,911	+1,458%	+$5.76M	0.27%	126
2021 Q4	$541K	Buy	+2,669	New	+$579K	0.03%	384

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Edgestream Partners's NKTR Position: Q2 2023 in Review

Edgestream Partners sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 31,802 shares — an estimated $335K sold.

Edgestream Partners first reported a position in NKTR in Q4 2021 and held it in 6 quarters. The position peaked at $4.05M in Q2 2022. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

Edgestream Partners reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
Edgestream Partners sold 31,802 Nektar Therapeutics shares in Q2 2023, an estimated $335K.
Edgestream Partners first reported a position in Nektar Therapeutics in Q4 2021 and held it in 6 quarters.
Edgestream Partners's Nektar Therapeutics position peaked at $4.05M in Q2 2022.
146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Edgestream Partners's 13F filing for Q2 2023, filed 10 Aug 2023.